National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011

Health Affairs

Volumn 33, Issue 10, 2014, Pages 1721-1727

  Conti, Rena M ^a   Fein, Adam J ^b   Bhatta, Sumita S ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b Pembroke Consulting Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE INHIBITOR; GENERIC DRUG; HORMONE; PRESCRIPTION DRUG; PROTEIN TYROSINE KINASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PATIENT; CHRONIC MYELOID LEUKEMIA; DRUG COST; DRUG MARKETING; DRUG USE; HEALTH CARE COST; HUMAN; PROSTATE CANCER; PROTECTION; TREND STUDY; UNITED STATES; ECONOMICS; MEDICARE; NEOPLASMS; ORAL DRUG ADMINISTRATION; STATISTICS AND NUMERICAL DATA;

ADMINISTRATION, ORAL; ANTINEOPLASTIC AGENTS; DRUG COSTS; HUMANS; MEDICARE PART D; NEOPLASMS; UNITED STATES;

EID: 84907815369     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2014.0001     Document Type: Article

References (42)

1. Lakdawalla DN, Sun EC, Jena AB, Reyes CM, Goldman GP, Phillipson TJ. An economic evaluation of the war on cancer. J Health Econ. 2010;29(3):333-46.
2. Mariotto AB, Yabroff KR, Shao Y, Feuer EJ, Brown ML. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011;103(2):117-28.
3. IMS Institute for Healthcare Informatics. Declining medicine use and costs: for better or worse? A review of the use of medicines in the United States in 2012. Falls Church (VA): The Institute; 2013 May.
4. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood). 2009;28(1):w151-60. DOI: 10.1377/hlthaff.28.1.w151.
5. Ryu AJ, Gibson TB, McKellar MR, Chernew ME. The slowdown in health care spending in 2009-11 reflected factors other than the weak economy and thus may persist. Health Aff (Millwood). 2013;32(5): 835-40.
6. Government Accountability Office. Medicare: high-expenditure Part B drugs [Internet]. Washington (DC): GAO; 2012 Oct 12 [cited 2014 Aug 7]. Available from: http://www.gao .gov/assets/650/649459.pdf
7. Genentech. The 2012 Genentech oncology trend report: perspectives from managed care, specialty pharmacy providers, oncologists, practice managers, and employers [Internet]. South San Francisco (CA): Genentech; [cited 2014 Aug 7]. Available from: http://www.amcp .org/WorkArea/DownloadAsset .aspx?id=16168
8. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med. 2009;360(6): 626-33.
9. Jacobson M, Earle CC, Price M, Newhouse JP. How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Aff (Millwood). 2010; 29(7):1391-9.
10. Conti RM, Rosenthal MB, Polite BN, Bach PB, Shi YC. Infused chemotherapy use in the elderly after patent expiration. Am J Manag Care. 2012;18(5):e173-8.
11. Express Scripts. Specialty trend forecast: cancer [Internet]. St. Louis (MO): Express Scripts; [cited 2014 Aug 7]. Available from: http://lab .express-scripts.com/drug-trendreport/ trend-forecast/forecastspecialty-therapy-classes/forecast-3-cancer
12. World Health Organization. The anatomical therapeutic chemical classification system with defined daily doses (ATC/DDD). Geneva: WHO; [cited 2014 Aug 7]. Available from: http://www.who.int/ classifications/atcddd/en/
13. World Health Organization. WHO Collaborating Centre for Drug Statistics Methodology [Internet]. Geneva: WHO; [last updated 2013 Dec 19; cited 2014 Aug 13]. Available from: http://www.whocc.no/ atc_ddd_index/?code=L&show description=yes
14. Food and Drug Administration. Approved drug products with therapeutic equivalence evaluations. 34th ed. [Internet]. Silver Spring (MD): FDA; 2014 [cited 2014 Aug 25]. Available from: http://www.fda.gov/ ucm/groups/fdagov-public/ @fdagov-drugs-gen/documents/ document/ucm071436.pdf
15. Food and Drug Administration. Drugs@FDA [Internet]. Silver Spring (MD): FDA; [cited 2014 Aug 25]. Available from: http:// www.accessdata.fda.gov/scripts/ cder/drugsatfda/index.cfm
16. CMS.gov. 2013 ASP drug pricing files [Internet]. Baltimore (MD): Centers for Medicare and Medicaid Services; [last modified 2014 Jun 11; cited 2014 Aug 7]. Available from: http://www.cms.gov/Medicare/ Medicare-Fee-for-Service-Part-BDrugs/ McrPartBDrugAvgSales Price/2013ASPFiles.html
17. Dougherty C. Introduction to econometrics. 3rd ed. New York (NY): Oxford University Press; 2007. p. 194.
18. To access the Appendix, click on the Appendix link in the box to the right of the article online
19. Martin AB, Lassman D, Washington B, Catlin A, National Health Expenditure Accounts Team. Growth in US health spending remained slow in 2010; health share of gross domestic product was unchanged from 2009. Health Aff (Millwood). 2012;31(1): 208-19.
20. National Cancer Institute. Cancer trends progress report-2011/2012 update [Internet]. Bethesda (MD): NCI; 2012 Aug [cited 2014 Aug 7]. Available for download from: http:// progressreport.cancer.gov/
21. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344(14): 1038-42.
22. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. J Clin Oncol. 2009;27(21):3472-9.
23. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-7.
24. Hess G, Bunjes D, Siegert W, Schwerdtfeger R, Ledderose G, Wassmann B, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005;23(30):7583-93.
25. Kantarjian HM, Giles F, Gattermann N, Bhalla K, Alimena G, Palandri F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome- positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007;110(10):3540-6.
26. Blanke CD, Demetri GD, von Mehren M, Heinrich MC, Eisenberg B, Fletcher JA, et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol. 2008;26(4):620-5.
27. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329-38.
28. Kindler HL, Campbell NP, Wroblewski K, Maki RG, D'Adamo DR, ChowWA, et al. Sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): final results of a University of Chicago phase II consortium trial. J Clin Oncol. 2011;29(15 Suppl): 10009.
29. Sawaki A, Nishida T, Doi T, Yamada Y, Komatsu Y, Kanda T, et al. Phase 2 study of Nilotinib as third-line therapy for patients with gastrointestinal stromal tumor. Cancer. 2011;117(20):4633-41.
30. Castellano D, del Muro XG, Pérez-Gracia JL, González-Larriba JL, Abrio MV, Ruiz MA, et al. Patientreported outcomes in a phase III, randomized study of sunitinib versus interferon-{alpha} as first-line systemic therapy for patients with metastatic renal cell carcinoma in a European population. Ann Oncol. 2009;20(11):1803-12.
31. Cella D, Michaelson MD, Bushmakin AG, Cappelleri JC, Charbonneau C, Kim ST, et al. Health-related quality of life in patients with metastatic renal cell carcinoma treated with sunitinib vs interferon-alpha in a phase III trial: final results and geographical analysis. Br J Cancer. 2010;102(4):658-64.
32. Hutson TE, Davis ID, Machiels JP, De Souza PL, Rottey S, Hong BF, et al. Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2010; 28(3):475-80.
33. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-34.
34. Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer. 2009;115(11):2438-46.
35. Conti RM, Bernstein AC, Villaflor VM, Schilsky RL, Rosenthal MB, Bach PB. Prevalence of off-label use and spending in 2010 among patentprotected chemotherapies in a population-based cohort of medical oncologists. J Clin Oncol. 2013;31(9): 1134-9.
36. Government Accountability Office. Brand-name prescription drug pricing: lack of therapeutically equivalent drugs and limited competition may contribute to extraordinary price increases [Internet]. Washington (DC): GAO; 2009 Dec [cited 2014 Aug 8]. Available from: http://www.gao.gov/new.items/ d10201.pdf
37. Aitken ML, Berndt ER. Medicare Part D at age five: what has happened to seniors' prescription drug prices? [Internet]. Parsippany (NJ): IMS Institute for Healthcare Informatics; 2011 Jul [cited 2014 Aug 21]. Available from: http://www.imshealth .com/ims/Global/Content/Home %20Page%20Content/IMS%20 News/IHII_Medicare_Part_D2.pdf
38. EMD Serono. EMD Serono specialty digest. 10th ed. [serial on the Internet]. Darmstadt (Germany): EMD Serono; [cited 2014 Aug 18; login required]. Available from: http:// specialtydigest.emdserono.com
39. Aitken ML, Berndt ER, Bosworth B, Cockburn IM, Frank R, Kleinrock M, et al. The regulation of prescription drug competition and market responses: patterns in prices and sales following loss of exclusivity [Internet]. Cambridge (MA): National Bureau of Economic Research; 2013 Oct [cited 2014 Aug 18]. (NBER Working Paper No. 19487). Available from: http://www.nber.org/papers/ w19487.pdf
40. Conti RM, Berndt ER. Specialty drug prices and utilization after loss of U.S. patent exclusivity, 2001-2007 [Internet]. Cambridge (MA): National Bureau of Economic Research; 2014 Mar [cited 2014 Aug 18]. (NBER Working Paper No. 20016). Available from: http://www.nber .org/papers/w20016.pdf
41. Banegas MP, Yabroff KR. Out of pocket, out of sight? An unmeasured component of the burden of cancer. J Natl Cancer Inst. 2013;105(4): 252-3.
42. Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014;32(4):306-11